Significantly Increased Specific Discharge Capacitance at Carbon Fibers Created via Architected Ultramicropores by Ying Zheng (170527)

Significantly Increased Specific Discharge Capacitance at Carbon Fibers Created via Architected Ultramicropores by Ying Zheng (170527)

Effect of different polyunsaturated fatty acids (PUFAs) in the inhibition of HCoV-229Eviral replication in MRC5 cells using antibody-based assay demonstrates significant inhibition of viral replication. by Amanda Watson (4447267)

Summary results of the logistic regression model M2-12 including the significant two-way interactions to maximise loglikelihood. by Dennis Ochola (11626912)

RMSE values of including and not including grocery store visits for alcohol sales prediction based on the RF model. by Yingjie Hu (1579000)

Subjects:

These files contain the STATA program codes used in the study. by Yeo Ju Sohn (18536198)

Subjects:

Degeneration Saline group presented with significant decreased final weight in relation to other groups. by Flavia Gomes Velasque Gama (21175112)

Statistically significant union pathways refer to the miRNAs with a decreased expression on day 5. by Morgana Lüdtke Azevedo (15285409)

Statistically significant union pathways refer to the miRNAs with a decreased expression on day 1. by Morgana Lüdtke Azevedo (15285409)

Photoreceptors undergo substantial changes in TF activity during aging. by Juan Jauregui-Lozano (12024868)

“…Schematic of differential transcription factor (TF) analysis approach using <i>diffTF</i>. D. Bar plot indicating the number of significant age-regulated TFs at each age relative to D10 (p-adj<0.001). …”

Trends in the days of sulfamethoxazole-trimethoprim therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in in-hospital mortality by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

Subjects:

Trends in the days of cefalexin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in the days of quinolone therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in the length of hospital stay by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

Subjects:

Trends in the days of macrolides therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in the days of amoxicillin and amoxicillin-clavulanate therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in the days of third-generation cephalosporin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in the incidence of <i>Clostridioides difficile</i> infection (CDI) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phas... by Naoya Itoh (6029276)

Subjects:

Trends in the incidence of extended-spectrum β-lactamase (ESBL)- producing Enterobacteriaceae per 1000 patients, by month, during the pre-intervention period (Phase 1) and interven... by Naoya Itoh (6029276)

Subjects: